BRIMS: the bridge between technology and your application
BRIMS and Mass Spec technology is leading the way in clinical translational research and protein biomarker discovery and validation. Thermo Fisher Scientific is advancing translational research through collaborations at the Biomarkers Research Initiatives in Mass Spectrometry (BRIMS) center in Cambridge, MA. The team works with top institutions and scientists to discover and validate Biomarkers. An increasing area of focus is clinical research and studying protein biomarkers associated to disease areas such as cancer and Alzheimer’s; hoping that we can one day diagnose disease by unlocking the secrets of proteomics.
Who is BRIMS?
Meet some of our team to learn more about our mission and vision to help scientists translate challenging clinical research to advance observations closer to the routine clinical laboratory.
Thermo Fisher is advancing proteomics and clinical translational research through collaborations at the Biomarkers Research Initiatives in Mass Spectrometry center in Cambridge, MA.
Dayana Argoti, Ph.D., a Senior Application Scientist at the Thermo Fisher Scientific BRIMS (Biomarker Research Initiatives in Mass Spectrometry) Center. Always interested in how things worked, Argoti made the switch to industry. She works in clinical toxicology methods development, bridging the small molecules approach with protein biomarkers.